Art Krieg, MD has worked in the oligonucleotide field for >30 years. Most recently he founded Checkmate Pharmaceuticals, where he is CSO. Previously Art was CSO at Sarepta until July 2014; co-founder and CEO at RaNA Therapeutics from 2011 to 2013; CSO of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011; and co-founder, CSO of Coley Pharmaceutical Group from 1997 to 2008. Art co-founded the first antisense journal, Nucleic Acid Therapeutics, which he edited for 16 years, and the Oligonucleotide Therapeutics Society, for which he recently served as President. He has published more than 250 scientific papers, and is an inventor on >50 issued US patents covering oligonucleotide technologies.